The combination of hyper-amplification and tumor mutational burden as a pan-cancer biomarker in patients treated with tislelizumab.Sanjeev Deva,Michael Millward,Michael Friedlander,Hui K. Gan, Lisa G. Hovarth,Jong-Seok Lee,Andrew Hill,Shahneen Sandhu, Liang Liang,Jingwen Shi, Yun Zhang,Yang Shi,Xiaopeng Ma,Xikun Wu,Zhirong Shen,Jayesh DesaiCANCER RESEARCH(2022)引用 0|浏览2暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要